CA-FORESCOUT-TECH
6.6.2022 15:02:12 CEST | Business Wire | Press release
Forescout Technologies, Inc. , the global leader in automated cybersecurity, today announced that it has signed a definitive agreement to acquire Cysiv , a cybersecurity innovator that uses its cloud platform to improve detection and response of true threats. With this acquisition, Forescout will leverage Cysiv’s threat detection engine to analyze a wealth of asset and network communications data automatically collected by Forescout’s platform. This comprehensive data across IT, IoT, OT and IoMT devices, as well as other essential data sources, enables better true threat detection and response so customers can operate more securely and efficiently. Upon the close of the acquisition, Cysiv will join Forescout.
“Organizations need to be able to reduce the billions of data points on their networks to a handful of actionable true threats – automatically. Together with Cysiv, Forescout will provide customers with the most powerful platform for automated cybersecurity across their digital terrains,” said Wael Mohamed, CEO of Forescout. “Upon close, the acquisition will help our customers leverage actionable threat intelligence from comprehensive data collected by Forescout and analyzed by Cysiv. We will receive far more than just great technology in this acquisition. The Cysiv team is exceptional, and our two organizations are highly complementary.”
Today, organizations are faced with the immense pressure to secure their networks. CIOs and CISOs have experienced rapid growth in the volume and diversity of managed and unmanaged devices, including IoT devices, that has given rise to increased risks and cybersecurity threats, coinciding with a drop in available cybersecurity resources. With the rapid adoption of cloud, and a cloud-first mindset that’s been accelerated by the work-from-anywhere shift of the past two years, enterprises are particularly concerned with managing threats to these fluid threat environments. This has resulted in organizations not being able to effectively manage the detection, investigation, escalation and response of true threats, particularly as the threat landscape and unmanaged device landscape have become more complex.
Existing solutions for threat detection and response, such as EDR, require the use of agents on managed devices. This means that organizations dependent on an agent-based approach for threat detection and response are not able to look for threats coming from the majority of their connected devices, particularly critical assets like IoT, IoMT and OT.
For over a decade, Forescout’s ability to deeply integrate into the fabric of customers’ networks has enabled it to collect real-time data for all connected assets and users, together with the communications among those assets and users. Customers have been asking Forescout to leverage this comprehensive data to provide greater insight into threats for all types of assets and to enable faster, more automated response and remediation.
“We have always been on a mission to provide better threat detection and faster response,” said Partha Panda, CEO and co-founder of Cysiv. “After successfully partnering together for the last year, we are thrilled to join Forescout as we continue on the next stage of our journey. The combination of Forescout and Cysiv will provide organizations with best-in-class threat detection together with automated incident prioritization and automated response.”
The acquisition is expected to close in July, 2022, subject to the satisfaction of closing conditions and receipt of applicable regulatory approvals and comes on the heels of its acquisition of CyberMDX which further strengthens Forescout’s industry-leading IT, IoT and OT device coverage with IoMT expertise.
About Forescout
Forescout Technologies, Inc. delivers cybersecurity automation across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types. The Forescout Continuum Platform provides complete asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets. www.forescout.com
Managing cyber risk, together.
© 2022 Forescout Technologies, Inc. All rights reserved. Forescout Technologies, Inc. is a Delaware corporation. A list of our trademarks and patents can be found at https://www.forescout.com/company/legal/intellectual-property-patents-trademarks . Other brands, products, or service names may be trademarks or service marks of their respective owners.
About Cysiv
Cysiv security operations center (SOC)-as-a-service provides enterprises with better detection and faster response of true threats. We do this by uniquely combining our cloud-native next generation SIEM, with a data-centric approach and a team of experts that operate as a seamless extension of your SOC. All of this is delivered as a subscription-based service, with predictable and flexible pricing, that can be operational in weeks. Cysiv’s modern approach to threat detection and response helps reduce risk, ensure compliance, and improve the efficiency, effectiveness and maturity of your security operations. To learn more, visit www.cysiv.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005321/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
